Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
NTRB 
Nutriband Inc (NTRB)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/15/2025: NTRB (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $15
1 Year Target Price $15
| 1 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -51.97% | Avg. Invested days 33 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 07/15/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 89.49M USD | Price to earnings Ratio - | 1Y Target Price 15 |
Price to earnings Ratio - | 1Y Target Price 15 | ||
Volume (30-day avg) 1 | Beta 1.2 | 52 Weeks Range 3.72 - 11.78 | Updated Date 07/14/2025 |
52 Weeks Range 3.72 - 11.78 | Updated Date 07/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.9 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -211.78% |
Management Effectiveness
Return on Assets (TTM) -36.45% | Return on Equity (TTM) -108.02% |
Valuation
Trailing PE - | Forward PE 370.37 | Enterprise Value 85915304 | Price to Sales(TTM) 37.31 |
Enterprise Value 85915304 | Price to Sales(TTM) 37.31 | ||
Enterprise Value to Revenue 35.82 | Enterprise Value to EBITDA -4.55 | Shares Outstanding 11130300 | Shares Floating 4420276 |
Shares Outstanding 11130300 | Shares Floating 4420276 | ||
Percent Insiders 76.37 | Percent Institutions 2.9 |
Upturn AI SWOT
Nutriband Inc
Company Overview
History and Background
Nutriband Inc. (NTRB) is a Nevada corporation specializing in transdermal drug delivery technology. Initially focused on abuse-deterrent transdermal patches, the company has expanded its product line. Founded with a commitment to innovative solutions for medication adherence and safety.
Core Business Areas
- Transdermal Drug Delivery: Development and commercialization of transdermal patches for various pharmaceutical and consumer health applications.
- Abuse-Deterrent Technology: Formulation of transdermal patches designed to deter abuse and misuse of controlled substances.
- Nutritional Supplements: Development of innovative supplements using transdermal and oral delivery methods.
Leadership and Structure
Gaston F. Khoury serves as the Chairman and CEO. The company operates with a small team focused on R&D, manufacturing partnerships, and regulatory approvals.
Top Products and Market Share
Key Offerings
- AvertRx Abuse-Deterrent Patch Technology: Abuse-deterrent transdermal patch technology designed to make opioid patches more difficult to misuse. No market share data is available. Competitors include pharmaceutical companies with abuse-deterrent opioid formulations.
- Nutriband Patch: A transdermal patch delivery system for supplements and OTC medications. Limited market share data is available. Competitors include companies producing vitamins and nutritional supplements, and other transdermal patch manufacturers.
Market Dynamics
Industry Overview
The transdermal drug delivery market is experiencing growth, driven by patient preference, ease of use, and controlled drug release. The nutritional supplement market is also experiencing growth, fueled by increased consumer awareness of health and wellness.
Positioning
Nutriband Inc. positions itself as an innovator in transdermal technology, particularly in abuse-deterrent and consumer health applications. Its competitive advantage lies in its patented AvertRx technology and focus on niche markets.
Total Addressable Market (TAM)
The transdermal drug delivery TAM is estimated to be in the billions of dollars. The nutritional supplements market is also a multi-billion dollar market. Nutriband Inc. aims to capture a portion of these markets through its niche products and patented technology.
Upturn SWOT Analysis
Strengths
- Patented AvertRx abuse-deterrent technology
- Focus on innovative transdermal solutions
- Potential for partnerships with larger pharmaceutical companies
- Established manufacturing partners.
Weaknesses
- Limited financial resources
- Small size and limited market reach
- Reliance on partnerships for manufacturing and distribution
- History of operating losses and limited revenue.
Opportunities
- Increasing demand for abuse-deterrent formulations
- Growing market for transdermal drug delivery
- Potential for expansion into new therapeutic areas
- Collaboration with major pharmaceutical companies.
Threats
- Competition from larger pharmaceutical companies
- Regulatory hurdles and lengthy approval processes
- Patent infringement risks
- Potential product liability claims.
Competitors and Market Share
Key Competitors
- TEVA
- MYL
- ALK
Competitive Landscape
Nutriband Inc. faces intense competition from larger, more established pharmaceutical companies. Its competitive advantage lies in its patented technology and focus on niche markets.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been limited by the company's focus on R&D and regulatory approvals.
Future Projections: Future growth projections depend on the successful commercialization of its products and partnerships.
Recent Initiatives: Recent initiatives include pursuing regulatory approvals for AvertRx, expanding its product line, and establishing manufacturing and distribution agreements.
Summary
Nutriband Inc. is a small, early-stage company with innovative transdermal technology, but it faces significant financial and competitive challenges. The company's success depends on securing regulatory approvals, establishing strategic partnerships, and successfully commercializing its products. While the patented AvertRx technology holds promise, the company's limited resources and intense competition pose risks. Strong market growth in Transdermal technology is promising and they need to capture more market share.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Nutriband Inc. SEC filings (10-K, 10-Q)
- Industry reports on transdermal drug delivery
- Market research on abuse-deterrent formulations
Disclaimers:
This analysis is based on publicly available information and should not be considered financial advice. Market share data is approximate and may vary.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Nutriband Inc
Exchange NASDAQ | Headquaters Orlando, FL, United States | ||
IPO Launch date 2017-11-30 | Founder, CEO & Director Mr. Gareth Sheridan | ||
Sector Healthcare | Industry Biotechnology | Full time employees - | Website https://www.nutriband.com |
Full time employees - | Website https://www.nutriband.com | ||
Nutriband Inc. develops a portfolio of transdermal pharmaceutical products in the United States. The company's lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. It also develops AVERSA buprenorphine and AVERSA methylphenidate, and other transdermal pharmaceutical products. The company has commercial development and clinical supply agreement with Kindeva Drug Delivery. The company was incorporated in 2016 and is headquartered in Orlando, Florida.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.